BFC Planning’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
SL
BFC Planning's KYMR Position: Q3 2026 in Review
BFC Planning increased its Kymera Therapeutics (KYMR) stake by 69% in Q3 2026, buying an estimated $1.26K and bringing the position to 27 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #2881.
BFC Planning first reported a position in KYMR in Q3 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- BFC Planning held 27 shares of Kymera Therapeutics worth $3.02K as of Q3 2026.
- BFC Planning bought 11 Kymera Therapeutics shares in Q3 2026, an estimated $1.26K.
- Kymera Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2881 holding.
- BFC Planning first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 5 quarters since.
- 215 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.